Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2016 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases

SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced novel research into complement biology that both expands the understanding of this...
November 03, 2016 09:01 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of Hematology

NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts have been accepted for poster presentation at the...
November 03, 2016 09:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs

Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016Achillion’s phase I MAD study with oral factor D inhibitor...
September 06, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop

NEW HAVEN, Conn., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of two posters which detailed novel preclinical research into...
September 01, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
August 11, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored Trial of Odalasvir, AL-335 and Simeprevir at the European Association for the Study of the Liver (EASL) Special Conference

NEW HAVEN, Conn., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that interim results from an ongoing phase 2a clinical trial, being conducted by...
August 09, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference

NEW HAVEN, Conn., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
August 04, 2016 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Second Quarter 2016 Financial Results

NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second...
June 10, 2016 03:30 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association

- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 - - Results support initiation...
May 03, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs

- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 – ...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right